Jounce Therapeutics Inc - ESG Rating & Company Profile powered by AI
The assessment of Jounce Therapeutics Inc uses data from across the web as well as from available documents by Jounce Therapeutics Inc. This article contains a Q&A section for Jounce Therapeutics Inc. Other corporations in the scoring peer group for Jounce Therapeutics Inc are displayed.
Jounce Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.6; made up of an environmental score of 8.0, social score of 4.8 and governance score of 4.0.
5.6
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 579 | Tonix Pharmaceuticals Holding Corp | 5.7 | High |
| 579 | VIVA Biotech Holdings | 5.7 | High |
| 602 | Jounce Therapeutics Inc | 5.6 | High |
| 602 | Celltrion Inc | 5.6 | High |
| 602 | Adaptimmune Therapeutics PLC | 5.6 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Jounce Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Jounce Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Jounce Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Jounce Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Jounce Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Jounce Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Jounce Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Jounce Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Jounce Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Jounce Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Jounce Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Jounce Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Jounce Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Jounce Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Jounce Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Jounce Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Jounce Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Jounce Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.